{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Will be assessed using Common Toxicity Criteria. Patients will be monitored by medical histories, physical examinations, ophthalmologic exams, and blood studies to detect potential toxicities from the treatment.\n\nthe number of patients experiencing a DLT are reported.","groups":[{"description":"Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV at 1 x 10\\^7\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis\n\nTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes: Given IV","id":"OG000","title":"Cohort 1 (Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 1)"},{"description":"Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV at 1 x 10\\^8\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis\n\nTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes: Given IV","id":"OG001","title":"Cohort 2 (Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 2)"},{"description":"Patients undergo leukapheresis on day -6 and receive cyclophosphamide IV over 2 hours on days -5 and -4. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV at 1 x 10\\^9\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis\n\nTGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes: Given IV","id":"OG002","title":"Cohort 3 (Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 3)"},{"description":"Patients undergo leukapheresis on day -6 and receive decitabine IV over 1 hour on days -6 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. Patients then receive TGFbDNRII-transduced autologous tumor infiltrating lymphocytes IV over 15 minutes on day 0. Eligible patients who showed initial response/disease control, may receive a second TGFbDNRII-transduced autologous tumor infiltrating lymphocytes infusion at any time after progression is confirmed.\n\nCyclophosphamide: Given IV at 1 x 10\\^9\n\nDecitabine: Given IV at 20 mg/m\\^2 x 3 days\n\nLaboratory Biomarker Analysis: Correlative studies\n\nLeukapheresis: Undergo leukapheresis","id":"OG003","title":"Cohort 4 (Decitabine, Cyclophosphamide, TCR/dnTGFbetaRII - Dose Level 3)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 30 days","title":"Number of Participants With Dose Limiting Toxicities","type":"PRIMARY","unitOfMeasure":"Participants"}